Oral tolerance and its role in clinical disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 32, Issue 3, 2001, Pages 237-255

  Spiekermann, G M ^a   Walker, W A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGIC DISEASE; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; CELIAC DISEASE; CELLULAR IMMUNITY; ENTERITIS; GASTROINTESTINAL DISEASE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE LYMPHATIC TISSUE; MUCOSAL IMMUNITY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; UVEITIS; VACCINATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS; AUTOIMMUNE DISEASES; CLONAL ANERGY; DISEASE MODELS, ANIMAL; GASTROINTESTINAL DISEASES; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; INTESTINAL MUCOSA; LYMPHOID TISSUE; PEYER'S PATCHES;

EID: 0035028778     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-200103000-00003     Document Type: Review

References (165)

1. Studies on the chemistry of anaphylaxis. III. Experiments with isolated proteins, especially those of hen's egg
2. Small intestinal permeability to macromolecules. Transmission of horseradish peroxidase into mesenteric lymph and portal blood
3. Induction of rapid T cell activation and tolerance by systemic presentation of an orally administered antigen
4. Oral administration of the bacterial superantigen staphylococcal enterotoxin B induces activation and cytokine production by T cells in murine gut-associated lymphoid tissue
5. Requirement for dual signals by anti-CD40 and IL-4 for the induction of nuclear factor-kappa B, IL-6, and IgE in human B lymphocytes
6. Transforming growth factor-beta 1 is a costimulator for IgA production
7. Antigen-specific TGF-beta1 secretion with bovine myelin oral tolerization in multiple sclerosis
8. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
9. The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression
10. Persistence of oral tolerance in mice fed ovalbumin is different for humoral and cell-mediated immune responses
11. Interleukin 10 secretion and impaired effector function of major histocompatibility complex class II-restricted T cells energized in vivo
12. Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis
13. Overview of the mucosal immune system
14. Systemic tolerance and secretory immunity after oral immunization
15. Kinetics of oral tolerance: Study of variables affecting tolerance induced by oral administration of antigen
16. Orally induced peripheral nonresponsiveness is maintained in the absence of functional Th1 or Th2 cells
17. Oral tolerance: Immune mechanisms and treatment of autoimmune diseases
18. T cell immunity to oral allergens
19. Oral tolerance: Immunologic mechanisms and treatment of autoimmune diseases
20. The role of antigen recognition and suppressor cells in mice with oral tolerance to ovalbumin
21. The immune response in cirrhotic rats. The induction of tolerance to orally administered protein antigens
22. Induction of oral tolerance to myelin basic protein in CD8-depleted mice: Both CD4+ and CD8+ cells mediate active suppression
23. CD4+ but not CD8+ T cells are required for the induction of oral tolerance
24. Lack of oral tolerance but oral priming for contact sensitivity to dinitrofluorobenzene in major histocompatibility complex class II-deficient mice and in CD4+ T cell-depleted mice
25. Gamma delta T lymphocytes regulate the induction and maintenance of oral tolerance
26. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis
27. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering
28. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance
29. TGF-beta induced by oral tolerance ameliorates experimental tracheal eosinophilia
30. Interferon-γ receptor deficient mice exhibit impaired gut mucosal immune responses but intact oral tolerance
31. T helper 2 cells are subject to high dose oral tolerance and are not essential for its induction
32. Tolerance and immunity in the intestinal immune system
33. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation
34. Enterically induced immunologic tolerance. I. Induction of suppressor T lymphocytes by intragastric administration of soluble proteins
35. Antigen-driven bystander suppression after oral administration of antigens
36. Direct measurement of anergy of antigen-specific T cells following oral tolerance induction
37. Antigen-specific T cell activation and proliferation during oral tolerance induction
38. CD4+ T cells energized by high dose feeding establish oral tolerance to antibody responses when transferred in SCID and nude mice
39. Dendritic cells and the control of immunity
40. IL-12 deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells
41. Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin-10 and induce the differentiation of T helper type 2 cells
42. Peripheral deletion of antigen-reactive T cells in oral tolerance
43. High dose oral tolerance in ovalbumin TCR-transgenic mice: Systemic neutralization of IL-12 augments TGF-beta secretion and T cell apoptosis
44. Murine model of oral tolerance. Induction of Fas-mediated apoptosis by blockade of interleukin-12
45. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: Influence of MHC binding affinity
46. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23)
47. Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope
48. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice
49. Cellular mRNA expression of interferon-gamma (IFN-gamma), IL-4 and transforming growth factor-beta (TGF-beta) in rats nasally tolerized against experimental autoimmune myasthenia gravis (EAMG)
50. The maturation of the immune system
51. Oral tolerance: Physiological basis and clinical applications
52. The absence of gut flora, the doses of antigen ingested and aging affect the long-term peripheral tolerance induced by ovalbumin feeding in mice
53. Role of nutrients and bacterial colonization in the development of intestinal host defense
54. Lack of oral tolerance in C3H/HeJ mice
55. Lipopolysaccharide (LPS) regulation of the immune response: LPS influence on oral tolerance induction
56. The requirement of intestinal flora for the development of an IgE production system fully susceptible to oral tolerance induction
57. Liver-associated lymphocytes expressing NK1.1 are essential for oral immune tolerance induction in a murine model
58. Gluten-sensitive enteropathy and other immunologically mediated enteropathies
59. Heterogeneity of celiac disease: Clinical, pathological, immunological, and genetic
60. Absolute linkage of celiac disease and dermatitis herpetiformis to HLA- DQ
61. Gliadin-specific, HLA-DQ (alpha 1*0501,beta 1*0201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients
62. TNF2, a polymorphism of the tumour necrosis-alpha gene promoter, is a component of the celiac disease major histocompatibility complex haplotype
63. Coeliac disease. Some still controversial aspects
64. Oral tolerance
65. In vitro activities of A-gliadin-related synthetic peptides: Damaging effect on the atrophic coeliac mucosa and activation of mucosal immune response in the treated coeliac mucosa
66. Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma
67. Immunological diseases of the GI tract
68. Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with celiac disease
69. Cytokine mRNA expression in the mucosa of treated coeliac patients after wheat peptide challenge
70. Interleukin-2 and interferon-gamma producing cells in the lamina propria in celiac disease
71. Analysis of interleukin-4 and interleukin-10 and their association with the lymphocytic infiltrate in the small intestine of patients with coeliac disease
72. A major role for matrix metalloproteinases in T cell injury in the gut
73. Priming of systemic and local delayed-type hypersensitivity responses by feeding low doses of ovalbumin to mice
74. Influence of diet on postweaning malabsorption and diarrhoea in the pig
75. In mice, gluten in maternal diet primes systemic immune responses to gliadin in offspring
76. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease
77. Molecular basis of celiac disease
78. Induction of rapid T cell activation and tolerance by systemic presentation of an orally administered antigen
79. Blockage of T-cell costimulation inhibits T-cell action in celiac disease
80. Regulation of immune responses by TGF-β
81. Latent transforming growth factor-β binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-β
82. The cow milk allergy complex: Overlapping disease profiles in infancy
83. Food allergy
84. Effector and regulatory lymphoid cells and cytokines in mucosal sites
85. Food allergies - Immunophysiology aspects
86. Food allergy
87. Hydrolysed cow's milk formulae. Allergenicity and use in treatment and prevention. An ESPACI position paper. European Society of Pediatric Allergy and Clinical Immunology
88. Oral cow milk challenge abolishes antigen-specific interferon-gamma production in the peripheral blood of children with atopic dermatitis and cow milk allergy
89. The frequency of cells secreting interferon-gamma and interleukin-4, -5, and -10 in the blood and duodenal mucosa of children with cow's milk hypersensitivity
90. Milk protein enteropathy after acute infectious gastroenteritis: Experimental and clinical observations
91. The immunologic basis for intestinal food allergy
92. Mucosal immunity in relation to the development of oral tolerance/sensitization
93. Clinical course of cow's milk protein allergy and intolerance
94. Failure to induce oral tolerance to protein antigens in neonatal mice can be corrected by transfer of adult spleen cells
95. Exquisite peptide specificity of oral tolerance in experimental autoimmune encephalomyelitis
96. Summary and future directions. Adverse reactions to food in infancy and childhood
97. A prospective study of cow's milk allergy in exclusively breast-fed infants. Incidence, pathogenetic role of early inadvertent exposure to cow's milk formula, and characterization of bovine milk protein in human milk
98. Epidemic of coeliac disease in Swedish children
99. T-cell development in the fetus and neonate
100. Ontogeny of murine macrophages: Functions related to antigen presentation
101. Development of immune function in the intestine and its role in neonatal diseases
102. A comparison of secretory antibodies in breast-fed and formula-fed infants over the first six months of life
103. Evidence for transmission of lymphocyte responses to tuberculin by breast-feeding
104. Effect of breast feeding on responses of systemic interferon and virus-specific lymphocyte transformation in infants with respiratory syncytial virus infection
105. Intestinal involvement in atopic disease
106. Experimental models of inflammatory bowel disease
107. Recent developments in the immunology of inflammatory bowel disease
108. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking
109. Tumor necrosis factor microsatellites define a Crohn's disease-associated haplotype on chromosome 6
110. Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease
111. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells
112. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease
113. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manicretion increased secretion of IL-5
114. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
115. Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease
116. T cells orchestrate intestinal mucosal shape and integrity
117. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease
118. Experimental models of intestinal inflammation
119. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice
120. Mucosal immune response: An overview
121. Interleukin-10-deficient mice develop chronic enterocolitis
122. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene
123. Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients
124. Granulomatous enterocolitis induced in rats by purified bacterial cell wall fragments
125. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum
126. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum
127. Hapten-induced model of murine inflammatory bowel disease: Mucosa immune responses and protection by tolerance
128. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12
129. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells
130. Crohn's disease
131. Inhibition of Th1 responses prevents inflammatory bowel disease in SCID mice reconstituted with CD45 RBhi CD4+ T cells
132. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease
133. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice
134. Persistent clonal expansions of peripheral blood CD4+ lymphocytes in chronic inflammatory bowel disease
135. Oral tolerance to myelin-basic protein induces regulatory TGF-β secreting cells in Peyer's patches of SJL mice
136. Oral tolerance to myelin-basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4, and prostaglandin E expression in the brain
137. Suppression of type II collagen induced arthritis by intragastric administration of soluble type II collagen
138. Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen
139. Modulation by cytokines of induction of oral tolerance to type II collagen
140. Suppression of diabetes in NOD mice by oral administration of porcine insulin
141. Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): Induction of protective tolerance in primed animals
142. Oral tolerance in disease
143. Oral tolerance in the treatment of inflammatory autoimmune diseases
144. Immunomodulation of experimental autoimmune diseases via oral tolerance
145. Down-regulation of the immune response to histocompatibility antigens and prevention of sensitization by skin allografts by orally administered alloantigen
146. The effect of oral immunization on corneal allograft survival
147. Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors
148. Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses
149. Complexities in the treatment of autoimmune disease
150. Induction of autoimmune diabetes by oral administration of autoantigen
151. Oral tolerance in humans. T cell but not B cell tolerance after antigen feeding
152. Effects of oral administration of type II collagen on rheumatoid arthritis
153. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial
154. Oral type II collagen treatment in early rheumatoid arthritis. A double- blind, placebo-controlled, randomized trial
155. Treatment of uveitis by oral administration of retinal antigens: Results of a phase I/II randomized masked trial
156. Molecular mimicry as a therapeutic approach for an autoimmune disease: Oral treatment of uveitis-patients with an MHC-peptide crossreactive with autoantigen - First results
157. Prevention of insulin-dependent diabetes mellitus: An overview of three trials
158. Insulin and the prevention of insulin-dependent diabetes mellitus
159. Immunologic effects of encapsulated short ragweed extract: A potent new agent for oral immunotherapy
160. Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: A double-blind study
161. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis
162. Oral administration of myelin basic protein is superior to myelin in suppressing established relapsing experimental autoimmune encephalomyelitis
163. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen
164. Cholera toxin B subunit: An efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance
165. Vaccination by inducing oral tolerance?